Topical anti-integrin therapy

IBD: Beyond Combination TherapyПодробнее

Positioning current and future anti-integrin therapies for IBDПодробнее

When and how to de-escalate therapy in IBDПодробнее

Getting to Zero: What will it take? Annual National CFAR Scientific Meeting Opening PlenaryПодробнее

Crohn's Disease: Recent and Emerging TherapiesПодробнее

IBD and Extra Intestinal Manifestations: Treatment OptionsПодробнее

Emerging Therapies in IBD - Dr. HanauerПодробнее

Positioning inhibitors of lymphocyte traffickingПодробнее

Case Discussion: When and how to modify IBD therapiesПодробнее

Baruch Kuppermann, ISOPT 2018 - Integrin peptide therapy in DMEПодробнее

Understanding the Contraindications to the Use of Immunomodulators and Biologics for IBDПодробнее

Therapeutic Insights from Integrin Knockout MiceПодробнее

IBD: Treatment Options for Extra Intestinal ManifestationsПодробнее

Should We Change How We Position Biologics for Use in Ulcerative Colitis?Подробнее

Optimizing IBD Management: New and Emerging Therapeutic TargetsПодробнее

Advances in Anti-Cytokine Therapy for IBD: The Role of IL-12/23 and IL-23 InhibitorsПодробнее

CON: We are not yet ready to use Vedolizumab in Pediatric IBDПодробнее

The Evolving Therapeutic Paradigm in IBD: Optimal Positioning of New and Emerging AgentsПодробнее

Should We Change How we Position Biologics for Use in Crohn’s Disease?Подробнее

Understanding the mechanisms of action of new agents: Implications for efficacy and safetyПодробнее